COLOPLAST A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 842.4 DKK | -1.96% |
|
-0.89% | +9.12% |
| May. 15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 |  |
| May. 07 | European shares hit one-month high as earnings take centre stage | RE |
| Sales 2024 * | 27.05B 3.93B | Sales 2025 * | 29.39B 4.28B | Capitalization | 189B 27.55B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.25B 763M | Net income 2025 * | 6.13B 892M | EV / Sales 2024 * | 7.72 x |
| Net Debt 2024 * | 19.4B 2.82B | Net Debt 2025 * | 17.9B 2.6B | EV / Sales 2025 * | 7.05 x |
| P/E ratio 2024 * |
36.2
x | P/E ratio 2025 * |
30.9
x | Employees | 15,930 |
| Yield 2024 * |
2.41% | Yield 2025 * |
2.62% | Free-Float | 58.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Coloplast A/S
More press releases
| 1 day | -1.96% | ||
| 1 week | -0.89% | ||
| Current month | -0.47% | ||
| 1 month | -2.43% | ||
| 3 months | -8.20% | ||
| 6 months | +4.72% | ||
| Current year | +9.12% |
1 week
838.40
881.00
1 month
804.00881.00
Current year
757.80977.60
1 year
689.20977.60
3 years
689.201 194.00
5 years
689.201 194.00
10 years
413.101 194.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 07-12-31 | |
| Director of Finance/CFO | 52 | 05-12-31 | |
| Chairman | 65 | 87-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 68-09-30 | |
Carsten Hellmann
BRD | Director/Board Member | 60 | 17-11-30 |
| Chairman | 65 | 87-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.81% | 200 M€ | +16.95% | ||
| 1.11% | 253 M€ | +5.90% | ||
| 0.96% | 48 M€ | +9.38% | ||
| 0.85% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 842.4 | -1.96% | 184,191 |
| 24-05-27 | 859.2 | +1.78% | 70,720 |
| 24-05-24 | 844.2 | -1.77% | 243,844 |
| 24-05-23 | 859.4 | -1.92% | 167,941 |
| 24-05-22 | 876.2 | +2.50% | 282,147 |
Delayed Quote Nasdaq Copenhagen, May 28, 2024 at 10:59 am EDT
More quotes
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows:
- hygiene products (43.4%): urine bags, plugs, urinary testing systems and sets, etc.;
- ostomy care products (36.8%): bags and equipment used following intestinal operations;
- wound care and skincare products (11.9%): wound dressings, bandages, creams and gels;
- voice and respiratory care products (7.9%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc.
Net sales are distributed geographically as follows: Denmark (1.4%), the United States (21%), the United Kingdom (14%), France (10.8%) and other (52.8%).
Calendar
2024-06-06
- Investor Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
842.4
DKK
Average target price
909.6
DKK
Spread / Average Target
+7.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.12% | 28.11B | |
| -35.22% | 3.03B | |
| -21.21% | 2.39B | |
| +5.74% | 2.18B | |
| -11.31% | 1.9B | |
| +21.11% | 1.88B | |
| +23.77% | 1.3B | |
| +13.02% | 1.23B | |
| -5.48% | 1.23B | |
| +21.08% | 1.22B |
- Stock Market
- Equities
- COLO B Stock
